
Gene therapy products present a unique set of challenges for the control of host cell protein impurities.
Andrew Hanneman, PhD, is scientific advisor, biologics testing with Charles River.
Gene therapy products present a unique set of challenges for the control of host cell protein impurities.
Published: July 15th 2021 | Updated: